MediWound Stock (NASDAQ:MDWD)
Previous Close
$18.03
52W Range
$14.14 - $22.50
50D Avg
$17.85
200D Avg
$18.41
Market Cap
$191.00M
Avg Vol (3M)
$99.44K
Beta
0.07
Div Yield
-
MDWD Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AARD | Aardvark Therapeutics, Inc. Common Stock |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. |
| GNFT | Genfit S.A. |
| SLS | SELLAS Life Sciences Group, Inc. |
| RNAC | Cartesian Therapeutics, Inc. |
| TARA | Protara Therapeutics, Inc. |
| IVVD | Invivyd, Inc. |
| OBIO | Orchestra BioMed Holdings, Inc. |
| IVA | Inventiva S.A. |
| EPRX | Eupraxia Pharmaceuticals Inc. |